Patient Resources

To help you keep your patients informed about COPD and motivated about managing it, we have compiled the resources below. Some you can download and print to hand out to your patients. Others are resources that can be found online.

Click on the tabs below for educational materials.

Breathe Well magazine
Breathe Well is a magazine with articles on topics of interest to people with COPD, including nutrition, smoking, exercise, medicine, and more. Click to download these recent articles.

Fan of several issues of Breathe Well magazine    Still Smoking? Why Cutting Back Isn't Enough (Vol. 7, #1)
   Don't Forget! Tips for Daily Medication Management (Vol. 9, #1)
   Asthma, COPD, or Both? It Does Make a Difference (Vol. 10, #2)
   Make Fitness Part of Your Daily Life (Vol. 10, #2)

Cover of SPIRIVA patient brochure
This informative brochure, "Getting the facts. Treating COPD," contains useful information about COPD and available treatments including SPIRIVA.

Download Patient Brochure

Your COPD patients can use this Activity Tracker to keep track of their daily activities for seven days.

Download Activity Tracker

To view and print PDF files, Adobe® Reader® must be installed on your computer. If you do not have Adobe Reader, click here to download it for free. Adobe® Reader® is a registered trademark of Adobe Systems Incorporated.

If you or someone you know needs help paying for medicine, click here.

Click here for full Prescribing Information and Patient's Instructions for Use

IMPORTANT PRODUCT INFORMATION

SPIRIVA HandiHaler is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

SPIRIVA HandiHaler is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, ie, ipratropium, or to any component of this product.

SPIRIVA HandiHaler is not indicated for the initial treatment of acute episodes of bronchospasm, ie, rescue therapy.

Immediate hypersensitivity reactions, including angioedema, may occur after administration of SPIRIVA. Additionally, inhaled medicines, including SPIRIVA, may cause paradoxical bronchospasm. If either of these occurs, treatment with SPIRIVA should be stopped and other treatments considered.

As an anticholinergic drug, SPIRIVA may potentially worsen symptoms and signs associated with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction, and should be used with caution in patients with any of these conditions.

As SPIRIVA is a predominantly renally excreted drug, SPIRIVA use should be monitored closely in patients with moderate to severe renal impairment (creatinine clearance of ≤50 mL/min).

SPIRIVA has been used concomitantly with other drugs commonly used in COPD (these include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids) without increases in adverse drug reactions. However, the co-administration of SPIRIVA with other anticholinergic-containing drugs (eg, ipratropium) has not been studied and is therefore not recommended.

The most commonly reported adverse drug reaction with SPIRIVA was dry mouth, which was usually mild and often resolved during continued treatment. Other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurred vision, glaucoma, urinary difficulty and urinary retention.

Privacy statement | Terms of use | Contact us | Home

SPU00209SV45603